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Abstract
Studies in methamphetamine (METH) abusers showed that the decreases in brain dopamine (DA) 
function might recover with protracted detoxification. However, the extent to which striatal DA 
function in METH predicts recovery has not been evaluated. Here we assessed whether striatal DA 
activity in METH abusers is associated with clinical outcomes. Brain DA D2 receptor (D2R) 
availability was measured with PET and [11C]raclopride in sixteen METH abusers both after 
placebo and after challenge with 60 mg oral methylphenidate (to measure DA release) to assess if 
it predicted clinical outcomes. For this purpose METH abusers were tested within 6 months of last 
METH use and then followed up for 9 months of abstinence. In parallel, 15 healthy controls were 
tested. METH abusers had lower D2R availability in caudate than controls. Both METH abusers 
and controls showed decreased striatal D2R availability after MPH and these decreases were 
smaller in METH than in controls in left putamen. The 6 METH abusers who relapsed during the 
follow up period had lower D2R availability in dorsal striatum than controls and had no D2R 
changes after MPH challenge. The 10 METH abusers who completed detoxification did not differ 
from controls neither in striatal D2R availability nor in MPH-induced striatal dopamine changes. 
These results provide preliminary evidence that low striatal DA function in METH abusers is 
associated with a greater likelihood of relapse during treatment. Detection of the extent of DA 
dysfunction may be helpful in predicting therapeutic outcomes.
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Introduction
Several preclinical studies have been reported on the deleterious effects of 
methamphetamine (METH) to dopamine (DA) cells. These studies have shown that METH 
can produce long-lasting changes on DA cell markers1,2 including decreases in brain DA 
content, tyrosine hydroxylase activity, DA uptake and DA transporter (DAT) levels.3,4
METH-induced changes in these DA markers have been associated with motor and learning 
deficits in rodents indicating that they are functionally significant.5,6 These DA effects have 
been interpreted as evidence of neurotoxicity, which is corroborated by studies that show 
METH-induced DA nerve terminal degeneration and reactive gliosis in striatum.7,8 More 
recent human imaging studies revealed correlation of memory deficits and decrement of 
DAT binding potential9 as well as reduced striatal DA D2 receptor (D2R) and impulsivity in 
METH abusers.10 Though it is generally believed that the effects of METH are limited to the 
terminals while sparing the soma, DA cell death has also been reported.11 Non-human 
primate studies report that the DA changes induced by METH are long lasting and present at 
least 6 months after drug administration.12 However, more recent work has documented 
significant recovery from METH-induced DA terminal changes. Studies investigating the 
recovery of DA brain neurotransmission after METH have shown results that vary from 
complete recovery to persistent long lasting changes. In rats, a marked reduction in baseline 
DA levels and amphetamine induced increases in DA release were observed one week after 
METH administration with recovery to normal values 12 months post treatment.13 
Significant, though not complete, recovery in DA function after METH administration was 
reported in a rodent study that showed marked depletions in DA (30% of controls) one week 
after METH that recovered 7 months post treatment (80% of controls).14 Similarly, imaging 
studies in non-human primates have shown significant recovery of DAT in animals exposed 
to METH 12–15 month post treatment.15 Our human positron emission tomography (PET) 
study showed increased DAT after protracted (12–17 months) abstinence.16 However, one 
non-human primate study documented striatal DA reductions still evident after 4 years post-
METH treatment.2
Both preclinical and clinical data provide evidence that METH is toxic to DA cells but that 
some of the damage may recover with detoxification. However, all of the clinical studies in 
METH users are based on findings showing decreases structural markers of DA terminals 
(transporters). In this study we used PET and [11C]raclopride to evaluate changes in 
extracellular DA in the striatum, which allowed direct assessment of the function of DA 
cells. PET with [11C]raclopridehas been used to study the involvement of DA in drug 
reward and addiction in the human brain.17 This includes studies that investigate the 
relationships between the ability of various drugs to modulate DA and their reinforcing 
effects, both in non-dependent and drug dependent individuals.18–20 Using [11C]raclopride, 
these studies have shown that stimulant drugs (i.e. methylphenidate, amphetamine) increase 
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DA in striatum in the human brain and that these responses are attenuated in drug-addicted 
subjects (review21). In this study PET imaging was performed after placebo and after oral 
methylphenidate (MPH, 60 mg). The METH abusers were initially tested within 6 months of 
last METH use and then followed for 9 months to assess if striatal DA function in METH 
predicted abstinence at the end of this time period.
Methods
Subjects
The Institutional Review Boards at the Stony Brook University/Brookhaven National 
Laboratory, at Harbor-University of California – Los Angles (HUCLA) Medical Center and 
at the Portland Veterans Administration Medical Center (PVAMC) approved the protocol. 
Written informed consent was obtained after the experimental procedure was explained to 
the subjects. METH abusers (3 female and 13 male, 39.2±4.9 year old) were recruited from 
HUCLA and PVAMC. METH was the subjects’ primary drug of abuse via the smoked or 
intravenous routes with a use frequency of at least 5 times/week and 0.5 g/day. Subjects that 
met a minimum 12-month history of METH abuse, DSM IV diagnosis for METH 
dependence, and a minimum 2-week period of detoxification and desired to stop using 
METH were recruited for the study. The control group (2 female and 13 male, 37.2±4.3 year 
old) was chosen to match the age range of the METH group. Exclusion criteria for both 
groups were: Present or past history of neurological or DSM IV Axis I psychiatric disease 
(apart from METH dependence), past or present history of affective disorder or ADD/
ADHD, abuse or dependence of drugs other than METH (excluding nicotine), medical 
illness that can affect brain function, past or present history of cardiovascular disease or high 
blood pressure, scores on the Hamilton Depression Scale > 15, which may indicate clinical 
depression. Urine screening tests for psychoactive drugs were performed to corroborate lack 
of drug use.
Study design
Each subject was tested with two [11C]raclopride scans [once after placebo and once after 60 
mg of oral methylphenidate (MPH), which was be given an hour prior to [11C]raclopride] to 
measure D2R availability and DA cell function. To avoid the carry over effects of MPH on 
subsequent scans, the [11C]raclopride PET scan was done first after placebo administration, 
and two hours later after MPH administration. Blood samples were obtained to measure 
plasma MPH concentration prior to and at 30 and 60 min after MPH. The plasma 
concentration of MPH was analyzed at Dr. Thomas Cooper's laboratory (Nathan Kline 
Institute, New York). In addition, cardiovascular response (continuously recording vital 
signs and EKG) and self-report rating of drug effects (high, anxiety, restlessness, alertness, 
drug effect) to pharmacological doses of MPH were obtained prior to and at every 5 minutes 
after placebo and MPH administration.
After the scan visits, the METH abusers were followed up in outpatient treatment facilities 
with random urine screening tests for psychoactive drugs for the 9 months that followed 
their PET scan study. All enrollees attended the same substance abuse day treatment 
program weekly. The program consists of an intensive outpatient drug rehabilitation 
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program that includes group and individual therapy and educational group sessions. The 
program includes early recovery skills and relapse prevention techniques. Family counseling 
is also available. Anger management and domestic violence awareness and prevention 
programs are also available at the center for up to 52 weekly sessions. The subjects received 
behavioral and psychological treatments. The subjects did not receive any medical 
treatments during the rehabilitation process.
PET Scanning
The PET scans were carried out on an HR+ Siemens tomograph using the 3-D acquisition 
mode. An external chinstrap device was used in addition to the individual headholder to 
minimize head motion during the scan. After a transmission image obtained for attenuation 
correction, scans were started immediately after injection of 5–10 mCi of [11C]raclopride 
and were carried out for a total of 60 minutes. The following scanning sequences were used: 
15 × 1 min.; 3 × 5 min.; 2 × 15 min. Each study included a measurement of the plasma 
clearance of total radioactivity and the measurement of the fraction of labeled tracer in 
plasma at selected times.
Image Analysis
Both manual drawn preselected regions of interest (ROIs) and Statistical Parametric 
Mapping (SPM) analyses were used. The ROI in dorsal striatum (caudate, putamen), ventral 
striatum and cerebellum were outlined by superimposing boundaries from a 
neuroanatomical atlas using a template22 Briefly, the regions of interest were initially 
outlined on the individual’s summed baseline [11C]raclopride image (images obtained 
between 15–60 min) and were then projected into the dynamic [11C]raclopride images to 
generate time–activity curves for the striatal regions (caudate, putamen and ventral striatum) 
and cerebellum. These time–activity curves for tissue concentration, along with the time–
activity curves for unchanged tracer in plasma were used to calculate [11C]raclopride’s 
transfer constant from plasma to brain (K1) and the total tissue distribution volume (VT). VT 
corresponds to the equilibrium measurement of the ratio of tissue concentration to plasma 
concentration in striatum and cerebellum using a graphical analysis technique for reversible 
systems23 The ratio of VT in striatum to that of VT in cerebellum corresponds to BPND +1 
where BPND is the in vivo binding potential (nondisplaceable). BPND is proportional to the 
number available binding sites Bavail/Kd. The response to drug administration (with 
placebo or with MPH) was quantified as the difference in Bmax/Kd with respect to the 
baseline, placebo condition.
Data Analysis
Differences in BPND between conditions were tested using a repeated measures ANOVA 
model with two conditions (placebo and MPH) and two groups (METH abuser and control) 
and post-hoc t-tests were then used to determine for which conditions the effects differed 
from the baseline condition. Plasma MPH concentration after oral administration were 
compared between the groups using Students’ t test. The effects of the MPH on the 
cardiovascular responses and behavioral self-reports were tested by comparing the scores 
obtained prior to the drug administration (placebo and MPH) and the averaged scores 
obtained between 70–100 min after oral administration using a repeated measures ANOVA. 
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Pearson product moment correlations were used to assess the relationship between the 
MPH-induced changes in BPND and the behavioral effects of the MPH. Using these 
statistics, we also tested whether clinical indices as cigarette smoking, years of METH use, 
amount of METH use and days of last METH use affected placebo or MPH-induced DA 
release in the abusers and as a function of abstinence vs. relapse.
D2R image template
A spatial normalization template matching the average D2R image contrast in the brain was 
developed using VT images from 34 healthy control subjects. These parametric images were 
obtained from [11C]raclopride PET scans collected with the same scanning sequence used 
for the present study. All images were carefully inspected to ensure whole brain coverage 
and exclude images with potential artifacts. A 12-parameter affine transformation with 16 
nonlinear iterations was used to register the images to the PD.mnc Montreal Neurological 
Institute (MNI) template provided with the SPM2 package. The dimensions of bounding box 
of the output volumes were 90:90, 126:90, and 72:108 along x, y, and z, respectively, and 
the voxel size was 2×2×2 mm3. Bilinear interpolation was used for reslicing. The average 
normalized and smoothed image (full with half maximum-FWHM = 8 mm) was computed 
to obtain the D2R image template in the MNI stereotactic space.
SPM analysis
Differences in D2R availability between MPH and placebo in the METH abusers and in the 
controls as well as between first visit and second visit were also tested on the voxel-level 
using the software package for SPM. Prior to the analysis, each subject’s VT image was 
converted to the Analyze format, mapped onto the MNI stereotactic space using the custom 
D2R image template and the 12-parameter affine transformation in SPM2 with a 2×2×2 
mm3 voxel size, smoothed via a Gaussian kernel with FWHM of 8 mm, and rescaled to the 
VT in cerebellum (VT ratio images). The VT ratio images were included into a repeated 
measures ANOVA model with two conditions (placebo and MPH) and two groups (METH 
abuser and control) for the group analyses in SPM2. Corrections for multiple comparisons 
were performed via the random field theory, an approach that is less conservative than the 
traditional Bonferroni method. Imaging voxels that were significantly different (p ≤ 0.005, 
minimum cluster size = 100 voxels) between conditions were identified. The statistical 
significance of condition × group interactions effects in the striatum were corrected for 
multiple comparisons using small volume corrections with a 10-mm diameter spherical 
volume in SPM. Only regions with corrected p-values ≤ 0.05 at the cluster-level were 
considered significantly. The MNI coordinates of the significant clusters were transformed 
to the Talairach space using a best-fit transform that minimizes bias associated with 
reference frame and scaling.24 The brain regions were labeled according to the Talairach 
daemon25 and a query range of 5-mm. We further checked the labels of the hubs using the 
Automated Anatomical Labeling atlas26 and the Brodmann atlas, which is included in the 
MRIcro software.
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Results
The METH abusers differed from the controls in that they had lesser years of education 
(12.7±1.6 vs. 14.3±8.1 years, p < 0.001) and there was a greater proportion of cigarette 
smokers (16 METH abusers vs. 4 controls, p < 0.001) and heavier cigarette smoking. Four 
METH abusers had moderate alcohol use and none of the controls use alcohol more than 
once per week. The METH abusers had a history of 13.1±7.2 years METH use and 1.2±1.0 
grams per day.
After placebo administration, the 16 METH abusers had lower D2R availability in caudate 
(2.5±0.2) than controls (2.8±0.3, p < 0.04), Table 1. Both METH abusers and controls 
reported greater ratings of drug effect (+1.5±1.7, p < 0.003; +2.3±2.8, p < 0.007) and 
alertness (+2.0±2.0, p < 0.001; +1.2±1.7, p < 0.02) after MPH than after placebo 
administration but the magnitude of these effects did not differ between groups. The controls 
but not the METH abusers reported greater ratings of “high” (+1.6±2.5, p < 0.03) after 
MPH. Neither group reported increased anxiety or restlessness after MPH. MPH 
administration increased pulse rate (METH abusers: +28.5±28.1%, p < 0.001; control: 
19.8±16.8%, p < 0.0004) and diastolic pressure (METH abusers: +6.3±10.7%, p < 0.03; 
subjects: +7.8±12.1%, p < 0.03) in both groups and increased systolic pressure in the METH 
abusers (+8.5±6.5%, p < 0.0001) but not in the controls (+3.8±9.2%, NS). However, the 
self-report ratings and cardiovascular changes after MPH were not significantly different 
between the groups. The plasma MPH concentrations at 30 and at 60 minutes were similar 
for the METH abusers (5.9±6.1, 19.1±6.2 ng/ml) and the controls (8±11.5, 21.8±8.9 ng/ml).
After MPH administration, both METH abusers (caudate: −4±7.3%, p < 0.04; putamen: 
−5.5±8.3%, p < 0.01; ventral striatum: −4.1±14%, p < 0.06) and controls had decreased D2R 
availability (caudate: −6.4±9.2%, p < 0.002; putamen: −10.5±10%, p < 0.001; ventral 
striatum: −9.5±13.5%, p < 0.007; Table 1) presumably reflecting DA increases. Comparison 
for groups’ interaction effects was only significant for MPH-induced DA in left putamen (p 
< 0.05). The MP-induced decreases in left putamen in METH abusers were significantly 
smaller than in controls. There was no association between placebo or MPH-induced DA 
release with clinical variables as cigarette smoking, years of METH use, amount of METH 
use and days of last METH use in the METH abusers. The plasma MPH levels were not 
associated with MPH-induced DA increases neither in METH abusers nor controls.
SPM analysis, using a correction for small volume and multiple comparisons (p < 0.005), 
showed significantly decreased D2R availability in striatum after MPH in both controls and 
METH abusers. The METH abusers had less decrement in putamen than controls 
[Coordinates in the MNI frame of reference: x = 38, y = −12, z = 6 mm; cluster volume = 
482 voxels (2-mm isotropic); statistical significance: Z-score = 2.5; p < 0.036, FDR-
corrected for multiple comparisons using a small volume correction (10-mm spherical 
volume), Figure 1]. There were no significant correlations between MPH-induced changes 
in BPND and the behavioral effects of MPH.
Six METH abusers (2 female and 4 male) relapsed after the PET scan visit. Four of these 
subjects had positive drug screens during the course of the study and two of the subjects 
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were lost to follow up but the center was given informal feedback that the subjects had 
relapsed. There were no demographic (age, education) or clinical differences (years of 
METH, alcohol, tobacco use, amount of METH, alcohol, tobacco use and days of last 
METH use) between the six METH abusers who relapsed and those who did not. There 
were also no differences in self-report ratings and cardiovascular response to MPH 
administration between those who relapsed and those who did not.
The six METH abusers who relapsed showed no D2R availability changes after MPH 
(caudate: −0.7±11%, NS; putamen: −0.5±10%, NS) whereas in 10 METH abusers who did 
not relapse MPH induced significant reduction in D2R availability (caudate: −6.6±5%, p < 
0.002; putamen: −8.5±5.6%, p < 0.001, Table 2). Post hoc analysis showed that METH 
abusers who relapsed had significant lower D2R availability in caudate (p < 0.014) and 
putamen (p < 0.015) at baseline and less DA release after MPH in putamen (treatment × 
diagnosis, p < 0.037). The amount of METH used by the 6 relapsed subjects did not 
correlate with baseline D2R availability and not with MPH-induced DA changes. The 10 
METH abusers who remained abstinent showed a trend for lower baseline D2R availability 
(p < 0.07) and less MPH-induced DA release (treatment × diagnosis, p < 0.07) in caudate 
than the controls.
Discussion
The results show that METH abusers had lower baseline D2R availability (placebo 
condition) in the caudate during early withdrawal, which replicates our prior findings in a 
different population of METH abusers.27 Animal studies have implicated DA D2 receptors 
located on striatal cells post-synaptic to the DA terminals in METH-induced toxicity.28,29 
Imaging studies have also shown that long-term METH abuse leads to extensive neuronal 
damage in the human brain, which is associated with persistent cognitive impairment.4
The subjects in this study received 60 mg MPH orally (0.75–1 mg/kg) and showed the 
expected increases in extracellular DA concentration secondary to MPH-induced DAT 
blockade. The DA increases were not correlated with self-ratings of high, which is 
consistent with our prior studies showing that MPH-induced DA increases are only 
associated with the “high” after intravenous but not after oral administration.22 The 
difference between the intravenous and oral administration of MPH with respect to their 
reinforcing effects most likely reflects the fact that the intravenous route leads to DA 
changes that are much faster than those observed after oral administration. Thus, the failure 
of oral MPH to induce a “high” is likely due to slower pharmacokinetics (slower brain 
uptake). This is because the speed with which drugs of abuse enter the brain is a key 
parameter that affects their reinforcing effects; the faster their brain uptake the more intense 
their reinforcing effects.30
The METH users showed lesser DA increases with MPH administration at early withdrawal 
than the controls. Since DA increases induced by MPH are dependent on DA release (a 
function of DA cell firing), it is likely that the difference may reflect decreased 
dopaminergic cell activity in the METH abusers. While evaluating the results of PET studies 
based on the competition of [11C]raclopride by endogenous DA, it is critical to remember 
Wang et al. Page 7
Mol Psychiatry. Author manuscript; available in PMC 2013 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
that the results merely reflect the fraction of D2R that is vacant and thus capable of binding 
the tracer. As a consequence, any reduction in D2R measured with this technique could 
reflect either decreases in levels of D2R and/or increases in DA release (competing for 
binding with [11C]raclopride for the D2R availability) in striatum (including nucleus 
accumbens). The increases in DA release could include pre-existing DA that was present 
prior to MPH administration or a combination of pre-existing DA plus DA that is released 
following MPH administration. If the presynaptic neuron in a METH abuser releases smaller 
amounts of DA (but fires at the same rate) the same observation would be seen. Other 
potential reasons for MPH-induced reductions in [11C]raclopride binding were decreased 
DA affinity for the D2R or decreased efficacy of MPH to prevent DA reuptake. However, 
the fact that the METH abusers and other drug-addicted subjects (i.e. cocaine and alcohol) 
show blunted reductions in specific binding (indicative of decrease DA release) when 
administered MPH indicates that these individuals had both a reduction in the levels of D2R 
as well as a decrease in DA release in striatum.20,31 Each deficiency would contribute to the 
overall decreased sensitivity in drug-addicted subjects to natural reinforcers.
In this study the METH abusers who showed greater DA increases after MPH administration 
during early withdrawal stayed sober and returned for the follow up visit. In contrast the 
METH users who showed no DA increases after MPH during early withdrawal relapsed. A 
similar association was recently reported by a study in cocaine abusers that showed lower 
baseline striatal D2R availability and MPH-induced DA increases in cocaine abusers who 
relapsed versus those who did not.32 Moreover in a prior study these same investigators had 
shown a negative correlation between the DA increases induced by amphetamine 
administration and their choice of cocaine over money; the lower the DA increases the more 
likely they were to select cocaine over a monetary reinforcer33. Since the study also reported 
reduced DA increases in cocaine abusers when compared with controls, this could indicate 
that drug-addicted subjects with the most severe decreases in brain dopaminergic activity are 
the ones more likely to choose drugs over other reinforcers (such as money). Therefore, the 
failure of DA depleted METH users to stay sober could occur because these individuals 
have a greater deficit in their ability to shift their reward directed behavior to natural 
reinforcers. In this study we found the METH users who relapsed had a blunted DA 
response to oral MPH in the dorsal striatum (caudate and putamen). During the development 
of drug addiction, drug-seeking behavior progresses from seeking the rewarding effects of 
drugs to being triggered and maintained by drug-associated cues and stressful 
environments.34 Prolonged drug seeking in vulnerable individuals results in habitual 
compulsive drug using behavior35,36 and in increased DA release in dorsal striatum 
triggered by conditioned drug-cues.36 In human cocaine abusers increases in DA elicited by 
cocaine-cues in the dorsal striatum are associated with the degree of drug craving and 
addiction severity.37,38 The dorsal striatum is also a major site that appears to be involved in 
relapse after prolonged abstinence from cocaine self-administration.39 Greater deficits in 
dorsal striatal DA transmission in METH abusers might promote habitual drug use and a 
loss in the ability to stay sober.
Limitations for this study are the relatively small sample sizes and even though we found 
group differences between relapse and control groups, we cannot ascribe a direct 
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relationship between D2R availability and the prediction of relapse. Prospective studies in a 
larger number of METH abusers are needed to determine the sensitivity of striatal DA 
measures in predicting relapse vs. abstinence. In this study we excluded METH abusers with 
any history of an axis I disorder other than METH dependence, which limits the 
generalization of our findings since co-morbidity in METH abusers is high. Also, most of 
the METH abusers were cigarette smokers and continued to smoke throughout the study, 
which might have confounded the comparisons with controls most of whom were non-
smokers.
Conclusion
The results revealed lower baseline striatal D2R availability and DA release in METH 
abusers than controls, which replicates our prior studies. We also show that METH abusers 
with better DA function during the early withdrawal period were more likely to stay sober at 
follow up than those with low striatal DA function. This coupled with similar findings in 
cocaine abusers32 suggest that poor DA function may be a biomarker that predicts a greater 
likelihood for relapse and a greater addiction severity. Thus early detection of the extent of 
DA dysfunction may be helpful in predicting clinical outcomes.
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Figure 1. 
A) Averaged DA D2 receptor availability (D2R) images with oral methylphenidate (MPH 
60 mg) and placebo between MPH and placebo (PL) of 16 METH abusers and 15 control 
subjects. The D2R images are scaled with respect to the maximum Vd ratio value of the 
control subjects with oral PL. The images are presented by using the rainbow scale, where 
red represents highest value and violet represents lowest value. Binding of [11C]raclopride is 
lowest in the METH abusers with oral MPH. B) SPM images (p < 0.005, small volume 
correction, multiple comparison) are superimposed on a structural MR image. The images of 
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differences between MPH and PL for the METH abusers and control subjects as well as the 
Δ (MPH – placebo) image between METH abusers and control subjects are presented by 
using yellow-red color, where yellow represents highest value and red represents lowest 
value.
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Figure 2. 
Averaged D2R images with MPH and placebo of 10 METH abusers with protracted 
abstinence and images of 6 METH abusers who relapse after the scan visit.
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